Merck Announces Major FOB Initiative With Its New Business Unit
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck BioVentures plans to launch follow-on version of Amgen’s Aranesp by 2012.
You may also be interested in...
Merck's Second-To-Market Renflexis Biosimilar Priced Below The First
Merck & Co. launched Renflexis in the US, marking the first time two biosimilars will compete for share against a brand, in this case J&J's Remicade.
Merck's Second-To-Market Renflexis Biosimilar Priced Below The First
Merck & Co. launched Renflexis in the US, marking the first time two biosimilars will compete for share against a brand, in this case J&J's Remicade.
Deals Of The Week Wonders: What Does Merck’s Latest Biosimilar Move Really Mean?
Plus a look at Roche/Chiasma, Chiesi/Cornerstone, Eisai/Valeant and more